SPRY (STOCKS)
ARS Pharmaceuticals, Inc. Common Stock
$5.650000
-0.450000 (-7.38%)
Prev close: $6.100000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Donn Casale
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $560.57M
- Employees
- 167
- P/E (TTM)
- -2.60
- P/B (TTM)
- 9.80
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
5
Strong Buy
4
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Jun 2026 (Q2)
|
$-0.63 | $-0.50 | -0.1276 | -25.40% |
|
Mar 2026 (Q1)
|
$-0.61 | $-0.54 | -0.0740 | -13.81% |
|
Dec 2025 (Q4)
|
$-0.42 | $-0.45 | +0.0305 | +6.77% |
|
Sep 2025 (Q3)
|
$-0.52 | $-0.48 | -0.0386 | -8.02% |
Financial Statements
| Revenues | $116.93M |
| Benefits Costs and Expenses | $255.66M |
| Costs And Expenses | $325.12M |
| Operating Expenses | $333.19M |
| Selling, General, and Administrative Expenses | $284.49M |
| Depreciation and Amortization | $1.62M |
| Research and Development | $15.23M |
| Other Operating Expenses | $32.25M |
| Operating Income/Loss | -$216.27M |
| Income/Loss From Continuing Operations After Tax | -$215.43M |
| Income/Loss From Continuing Operations Before Tax | -$138.73M |
| Net Income/Loss | -$215.43M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$215.43M |
| Net Income/Loss Available To Common Stockholders, Basic | -$215.43M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$2.18 |
| Diluted Earnings Per Share | -$2.18 |
| Basic Average Shares | 198,265,854 |
| Diluted Average Shares | 198,265,854 |
| Assets | $249.50M |
| Current Assets | $211.51M |
| Inventory | $30.73M |
| Other Current Assets | $180.78M |
| Noncurrent Assets | $37.99M |
| Fixed Assets | $2.09M |
| Intangible Assets | $13.90M |
| Other Non-current Assets | $22.00M |
| Liabilities | $236.98M |
| Current Liabilities | $60.86M |
| Accounts Payable | $5.20M |
| Wages | $5.00M |
| Other Current Liabilities | $50.67M |
| Noncurrent Liabilities | $176.12M |
| Long-term Debt | $96.68M |
| Other Non-current Liabilities | $79.44M |
| Equity | $12.51M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $12.51M |
| Liabilities And Equity | $249.50M |
| Net Cash Flow From Operating Activities | -$196.41M |
| Net Cash Flow From Operating Activities, Continuing | -$196.41M |
| Net Cash Flow From Investing Activities | $48.50M |
| Net Cash Flow From Investing Activities, Continuing | $48.50M |
| Net Cash Flow From Financing Activities | $104.53M |
| Net Cash Flow From Financing Activities, Continuing | $104.53M |
| Net Cash Flow | -$43.38M |
| Net Cash Flow, Continuing | -$43.38M |
| Comprehensive Income/Loss | -$215.53M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$215.53M |
| Other Comprehensive Income/Loss | -$215.53M |